Ozempic vs Retatrutide: Eli Lilly claims 'more than double' the weight loss in latest trial — What's next?

Eli Lilly said on Wednesday that its experimental next-generation obesity drug, retatrutide, outperformed Novo Nordisk's Ozempic on blood sugar control and delivered more than…

By Maren Holt · Senior Reporter, GLP-1

Oct 29 05:03 ETSource: Livemint

From the source

Ozempic vs Retatrutide: Eli Lilly claims 'more than double' the weight loss in latest trial — What's next?
Eli Lilly said on Wednesday that its experimental next-generation obesity drug, retatrutide, outperformed Novo Nordisk's Ozempic on blood sugar control and delivered more than double the weight loss in a diabetes study.

Read at livemint.com

Source URL https://www.livemint.com/science/health/ozempic-vs-retatrutide-eli-lilly-claims-more-than-double-the-weight-loss-in-latest-trial-whats-next-11793263083541.html